scholarly article | Q13442814 |
P356 | DOI | 10.1128/AAC.02479-16 |
P8608 | Fatcat ID | release_g6impbrmd5ekpgy3fxwe5qyrku |
P953 | full work available at URL | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5444178 |
P932 | PMC publication ID | 5444178 |
P698 | PubMed publication ID | 28416540 |
P50 | author | Seyedmojtaba Seyedmousavi | Q40062294 |
Willem Melchers | Q56859383 | ||
Paul E. Verweij | Q70514014 | ||
P2093 | author name string | Johan W Mouton | |
P2860 | cites work | Azole Resistance in Aspergillus fumigatus: Can We Retain the Clinical Use of Mold-Active Antifungal Azoles? | Q28082352 |
Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis | Q28217179 | ||
Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America | Q28263689 | ||
Microbial Pathogens in the Fungal Kingdom | Q28740823 | ||
Triazole Resistance in Aspergillus Species: An Emerging Problem | Q30235566 | ||
Emergence of azole resistance in Aspergillus fumigatus and spread of a single resistance mechanism | Q30853962 | ||
Efficacy of posaconazole against three clinical Aspergillus fumigatus isolates with mutations in the cyp51A gene. | Q33613758 | ||
Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America | Q34532546 | ||
Pharmacokinetics and pharmacodynamics of posaconazole for invasive pulmonary aspergillosis: clinical implications for antifungal therapy | Q34754956 | ||
Aspergillosis. Pathogenesis, clinical manifestations, and therapy | Q35038459 | ||
Posaconazole prophylaxis in experimental azole-resistant invasive pulmonary aspergillosis. | Q35076830 | ||
Systemic mycoses in the immunocompromised host: an update in antifungal therapy | Q35093104 | ||
Review of newer antifungal and immunomodulatory strategies for invasive aspergillosis | Q35219726 | ||
Pharmacodynamics of isavuconazole in an Aspergillus fumigatus mouse infection model | Q35385554 | ||
Clinical implications of azole resistance in Aspergillus fumigatus, The Netherlands, 2007-2009. | Q35848799 | ||
Underlying disorders and their impact on the host response to infection | Q36291747 | ||
Animal models testing monotherapy versus combination antifungal therapy: lessons learned and future directions | Q36521174 | ||
Pharmacodynamics and dose-response relationships of liposomal amphotericin B against different azole-resistant Aspergillus fumigatus isolates in a murine model of disseminated aspergillosis | Q36757621 | ||
When primary antifungal therapy fails | Q37141191 | ||
Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/ | Q37164067 | ||
Epidemiology and Molecular Characterizations of Azole Resistance in Clinical and Environmental Aspergillus fumigatus Isolates from China. | Q37287782 | ||
Lessons from animal studies for the treatment of invasive human infections due to uncommon fungi. | Q37865279 | ||
Therapeutic drug monitoring of voriconazole and posaconazole for invasive aspergillosis. | Q38140015 | ||
Breakpoints for antifungal agents: an update from EUCAST focussing on echinocandins against Candida spp. and triazoles against Aspergillus spp. | Q38195132 | ||
The role of azoles in the management of azole-resistant aspergillosis: from the bench to the bedside. | Q38234496 | ||
Systemic Antifungal Agents: Current Status and Projected Future Developments. | Q38796140 | ||
Occurrence of triazole-resistant Aspergillus fumigatus with TR34/L98H mutations in outdoor and hospital environment in Kuwait | Q38863185 | ||
Changes in the epidemiological landscape of invasive mould infections and disease | Q38868919 | ||
Therapeutic outcome in invasive aspergillosis | Q38970340 | ||
Azole-resistant invasive aspergillosis in a patient with acute myeloid leukaemia in Germany. | Q40274784 | ||
First description of azole-resistant Aspergillus fumigatus due to TR46/Y121F/T289A mutation in France. | Q41280441 | ||
Multi-triazole-resistant Aspergillus fumigatus infections in Australia | Q41321727 | ||
Prospective multicenter international surveillance of azole resistance in Aspergillus fumigatus. | Q41542809 | ||
First Detection of TR34 L98H and TR46 Y121F T289A Cyp51 Mutations in Aspergillus fumigatus Isolates in the United States | Q41842226 | ||
Effect of neutropenia and treatment delay on the response to antifungal agents in experimental disseminated candidiasis | Q42112304 | ||
Multi-azole-resistant Aspergillus fumigatus in the environment in Tanzania. | Q42206937 | ||
First reported case of azole-resistant aspergillus fumigatus due to the TR/L98H mutation in Germany | Q42383280 | ||
SCH56592 treatment of murine invasive aspergillosis | Q42538220 | ||
Frequency and evolution of Azole resistance in Aspergillus fumigatus associated with treatment failure | Q42555868 | ||
Multiple Fungicide-Driven Alterations in Azole-Resistant Aspergillus fumigatus, Colombia, 2015. | Q42922120 | ||
Azole-resistant Aspergillus fumigatus, Iran. | Q43171569 | ||
Azole resistance in Aspergillus: a growing public health menace | Q43607400 | ||
Multidrug resistance in Aspergillus fumigatus. | Q44261807 | ||
Multiple-azole-resistant Aspergillus fumigatus osteomyelitis in a patient with chronic granulomatous disease successfully treated with long-term oral posaconazole and surgery. | Q44318186 | ||
EUCAST technical note on Aspergillus and amphotericin B, itraconazole, and posaconazole | Q45152541 | ||
Azole-resistant central nervous system aspergillosis. | Q46094844 | ||
Breakthrough pulmonary Aspergillus fumigatus infection with multiple triazole resistance in a Spanish patient with chronic myeloid leukemia | Q46487039 | ||
Voriconazole-Susceptible and Voriconazole-Resistant Aspergillus fumigatus Coinfection. | Q53789869 | ||
Aspergillosis—and a misleading sensitivity result | Q63914856 | ||
Invasive aspergillosis in critically ill patients without malignancy | Q80269940 | ||
Comparison of anidulafungin's and fluconazole's in vivo activity in neutropenic and non-neutropenic models of invasive candidiasis | Q82740226 | ||
P433 | issue | 6 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | Aspergillus fumigatus | Q134359 |
aspergillosis | Q259626 | ||
amphotericin B | Q412223 | ||
immunosuppression | Q1455316 | ||
P577 | publication date | 2017-05-24 | |
P1433 | published in | Antimicrobial Agents and Chemotherapy | Q578004 |
P1476 | title | In Vivo Efficacy of Liposomal Amphotericin B against Wild-Type and Azole-Resistant Aspergillus fumigatus Isolates in Two Different Immunosuppression Models of Invasive Aspergillosis | |
P478 | volume | 61 |
Search more.